Mineralys Therapeutics Management
Management criteria checks 1/4
Mineralys Therapeutics' CEO is Jon Congleton, appointed in Nov 2020, has a tenure of 4.17 years. total yearly compensation is $5.36M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 1.8% of the company’s shares, worth $11.42M. The average tenure of the management team and the board of directors is 2 years and 2.7 years respectively.
Key information
Jon Congleton
Chief executive officer
US$5.4m
Total compensation
| CEO salary percentage | 9.7% |
| CEO tenure | 4.2yrs |
| CEO ownership | 1.8% |
| Management average tenure | 2yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
Oct 07
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Sep 17We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jun 06Mineralys Therapeutics: A Story To Keep An Eye On
Mar 18Mineralys: 2nd Half 2024 Hypertension Data Readout
Feb 09We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
Nov 12We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jul 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$153m |
| Jun 30 2024 | n/a | n/a | -US$120m |
| Mar 31 2024 | n/a | n/a | -US$91m |
| Dec 31 2023 | US$5m | US$517k | -US$72m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$2m | US$417k | -US$30m |
| Sep 30 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$675k | US$346k | -US$19m |
Compensation vs Market: Jon's total compensation ($USD5.36M) is above average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.
CEO
Jon Congleton (61 yo)
4.2yrs
Tenure
US$5,355,257
Compensation
Mr. Jon Congleton serves as Chief Executive Officer and Director at Mineralys Therapeutics, Inc. since November 2020. He serves as an Operating Partner at Catalys Pacific. He was the Chief Executive Office...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 5.7yrs | US$630.13k | no data | |
| CEO & Director | 4.2yrs | US$5.36m | 1.8% $ 11.4m | |
| CFO & Secretary | 2.8yrs | US$2.19m | 0.48% $ 3.0m | |
| Chief Medical Officer | 4yrs | US$2.35m | 0.29% $ 1.9m | |
| Executive Vice President of Operations | 2yrs | no data | no data | |
| Vice President of Human Resources | less than a year | no data | no data | |
| Senior Vice President of CMC | no data | no data | no data | |
| Senior Vice President of Quality Assurance | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | no data | no data | no data | |
| Senior Vice President of Clinical Operations | 2yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Management: MLYS's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 5.7yrs | US$630.13k | no data | |
| CEO & Director | 4.2yrs | US$5.36m | 1.8% $ 11.4m | |
| Independent Director | 1.3yrs | US$427.02k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$607.30k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 1.3yrs | US$428.52k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 2.7yrs | US$611.91k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | no data | no data |
2.7yrs
Average Tenure
56yo
Average Age
Experienced Board: MLYS's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 22:18 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mineralys Therapeutics, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Charlie Yang | BofA Global Research |
| Geoffrey Meacham | BofA Global Research |